KatherineBarnettPetersMDPhD FAAN

Neurooncology

Associate Professor, Neurology and Neurosurgery, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University School of Medicine

Join to view full profile

Dr. Peters is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Peters' full profile

Already have an account?

Office
047 Baker House
Durham, NC 27710
Phone+1 919-684-6173
Is this information wrong?

Education & Training

Johns Hopkins UniversityResidency, Neurology, 2004 - 2007
Johns Hopkins UniversityInternship, Internal Medicine, 2003 - 2004
Stanford University School of MedicineClass of 2003, MD PhD

Certifications & Licensure

NC State Medical License 2008 - 2024
MD State Medical License 2006 - 2011
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas Start of enrollment: 2004 Apr 01
Completed
Phase 1
Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas Start of enrollment: 2007 Aug 01
Completed
Phase 2
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas Start of enrollment: 2009 Oct 01
Completed
Phase 1, Phase 2
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme Start of enrollment: 2009 Nov 01
Completed
Phase 2
AMG 102 and Avastin for Recurrent Malignant Glioma Start of enrollment: 2010 Aug 01
Completed
Phase 2
Effects of Steroid Tapering on Functional Capacity and Neurocognition Start of enrollment: 2010 Jun 01
Withdrawn
Not Applicable
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
Low Dose Naltrexone for Glioma Patients Start of enrollment: 2011 May 01
Completed
Phase 2
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide Start of enrollment: 2014 Jun 24
Completed
Phase 2
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Start of enrollment: 2013 Jan 01
Completed
Phase 2
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29
Recruiting
Phase 2
Roles: Principal Investigator, Contact
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment Start of enrollment: 2023 Jun 27
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Comparison of differing dose levels of methotrexate for patients with primary central nervous system lymphoma.
Daniel P Schrum, Meredith T Moorman, Zhiguo Li, Mairead Dillon, Katherine B Peters, Matthew McKinney, Mallika P Patel> ;Journal of Oncology Pharmacy Practice. 2024 Apr 1
4 citations
Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years.
Meagan V Lew, Yi Ren, Yen P Lowder, Sharareh Siamakpour-Reihani, Sendhilnathan Ramalingam, Kristi M Romero, Jillian C Thompson, Lauren M Bohannon, Jackie McIntyre, Hel...> ;Transplantation and Cellular Therapy. 2022 Aug 1
3 citations
Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.
Katherine B Peters, Mary L Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, James E Herndon 2nd, Elizabeth S Miller, Maria W Freeman, Dina M Randazzo, Annick Desjar...> ;Supportive Care in Cancer. 2022 Apr 1
4 citations
Pineal Parenchymal Tumors of Intermediate Differentiation Treated With Ventricular Radiation and Temozolomide.
Justin Low, John P. Kirkpatrick, Katherine B. Peters> ;Advances in Radiation Oncology. 2022 Jan 1
5 citations
Preservation of neurocognitive function in the treatment of brain metastases.
Michael W. Parsons, Katherine B. Peters, Scott R. Floyd, Paul D. Brown, Jeffrey S. Wefel> ;Neuro-Oncology Advances. 2021 Nov 27
3 citations
Targeting BRAF-mutant glioma: reflections on the ROAR trial.
Katherine B. Peters> ;The Lancet. Oncology. 2021 Nov 24
1 citations
Correction to: Caregiver burden by treatment and clinical characteristics of patients with glioblastoma.
Trang H. Au, Connor Willis, Maija Reblin, Katherine B. Peters, Phioanh L. Nghiemphu, Jennie Taylor, Howard Colman, Adam L. Cohen, D. Ryan Ormond, Arnab Chakravarti, Ni...> ;Supportive Care in Cancer. 2021 Nov 18
Availability and role of clinical pharmacists in ambulatory neuro-oncology
Mallika P Patel, Eric S. Lipp, Elizabeth S Miller, Patrick Healy, James E. Herndon, Katherine B. Peters> ;Neuro-Oncology Practice. 2021 Oct 22
Multi-joint steroid-induced avascular necrosis in a malignant brain tumor patient.
Jessica M. Lewis-Gonzalez, Mallika P Patel, Katherine B. Peters> ;CNS Oncology. 2021 Oct 12
9 citations
Caregiver burden by treatment and clinical characteristics of patients with glioblastoma
Trang H. Au, Connor Willis, Maija Reblin, Katherine B. Peters, Phioanh L. Nghiemphu, Jennie Taylor, Howard Colman, Adam L. Cohen, D. Ryan Ormond, Arnab Chakravarti, Ni...> ;Supportive Care in Cancer. 2021 Sep 11
2 citations
Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis.
Jennifer H. Kang, Christa B. Swisher, Evan Buckley, James E. Herndon, Eric S. Lipp, John P. Kirkpatrick, Annick Desjardins, Henry S. Friedman, Margaret Johnson, Dina R...> ;CNS Oncology. 2021 Sep 1
83 citations
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
Ingo K. Mellinghoff, Marta Penas-Prado, Katherine B. Peters, Howard A. Burris, Elizabeth A. Maher, Filip Janku, Gregory M. Cote, Macarena I. de la Fuente, Jennifer Cla...> ;Clinical Cancer Research. 2021 Aug 15
4 citations
Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.
Dina Randazzo, Frances McSherry, James E. Herndon, Mary Lou Affronti, Eric S. Lipp, Elizabeth S Miller, Sarah Woodring, Patrick Healy, Jennifer G. Jackman, Brian T. Cr...> ;Neuro-Oncology Practice. 2021 May 26
2 citations
Palliative Care Use for Critically Ill Patients With Brain Metastases.
Jennifer H. Kang, Meghan Price, Tara Dalton, Luis Ramirez, Peter E. Fecci, Arif H. Kamal, Margaret Johnson, Katherine B. Peters, Courtney Rory Goodwin> ;Journal of Pain and Symptom Management. 2021 May 13
3 citations
Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.
Justin Low, Shih-Hsiu Wang, Katherine B. Peters> ;CNS Oncology. 2021 Apr 28
1 citations
A broad perspective on evaluating bias in the neuro-oncology workplace
Priya Kumthekar, Erin M. Dunbar, Katherine B. Peters, Priscilla K. Brastianos, Alyx B. Porter> ;Neuro-Oncology. 2021 Mar 25
Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis.
Jessica W. Lee, John P. Kirkpatrick, Frances McSherry, James E. Herndon, Eric S. Lipp, Annick Desjardins, Dina Randazzo, Henry S. Friedman, David M. Ashley, Katherine ...> ;Frontiers in Oncology. 2021 Feb 25
110 citations
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Lakshmi Nayak, Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot, Leia Nghiemphu, Thomas Kaley, Howard Colman, Christine McClu...> ;Clinical Cancer Research. 2021 Feb 15
3 citations
What is New in Neuro-oncology?
Jigisha P. Thakkar, Vikram C. Prabhu, Katherine B. Peters, Rimas V. Lukas> ;Neurologic Clinics. 2021 Feb 1
1 citations
When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis
Breanna J Taylor, Mallika P Patel, Katherine B. Peters> ;CNS Oncology. 2021 Jan 15
71 citations
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
Matthias Gromeier, Michael C. Brown, Gao Zhang, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, Hai Yan, Yiping He, Annick Desjardins, James E. Herndon, Frederick S. V...> ;Nature Communications. 2021 Jan 13
5 citations
The State of Neuro-Oncology During the COVID-19 Pandemic: A Worldwide Assessment
Maciej M. Mrugala, Quinn T. Ostrom, Shelley M. Pressley, Jennie Taylor, Alissa A. Thomas, Jeffrey S. Wefel, Scott L. Coven, Alvina Acquaye, Chas Haynes, Sameer Agnihot...> ;Neuro-Oncology Advances. 2021 Jan 1
1 citations
Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States.
Syed M Adil, Sarah E Hodges, Ryan Edwards, Lefko T Charalambous, Zidanyue Yang, Musa Kiyani, Alexis Musick, Beth Parente, Hui-Jie Lee, Katherine B. Peters, Peter E. Fe...> ;Neuro-Oncology Practice. 2020 Dec 4
54 citations
Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complicati...
Samantha J Mayo, Maryam B. Lustberg, Haryana M. Dhillon, Zev M. Nakamura, Deborah H. Allen, Diane Von Ah, Michelle C. Janelsins, Alexandre Chan, Karin Olson, Chia Jie ...> ;Supportive Care in Cancer. 2020 Nov 24
240 citations
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Louis B. Nabors, Jana Portnow, Manmeet Ahluwalia, Joachim Baehring, Henry Brem, Steven Brem, Nicholas Butowski, Jian Campian, Stephen W. Clark, Andrew J. Fabiano, Pete...> ;Journal of the National Comprehensive Cancer Network. 2020 Nov 2
Join now to see all

Abstracts/Posters

Geriatric Assessment Identifies Impairments in Younger Candidates for Allogeneic Hematopoietic Stem Cell Transplantation
Katherine B. Peters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures